Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Sanofi’s acquisition of Vigil Neuroscience involves purchasing the company for $8 per share in cash, along with an additional $2 in contingent value rights, pending the commercial success of ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

In other recent news, Vigil Neuroscience is set to be acquired by Sanofi (NASDAQ:SNY) for $8 per share, with an additional $2 in contingent value rights, totaling an equity value of approximately ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Foxconn Technology (OTCPK:FXCOF) is among potential bidders for UTAC Holdings in a transaction that could value the Singapore-based semiconductor assembly and testing company at about $3 billion.

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...